Trial Profile
A Phase II Study of Pazopanib and Oral Topotecan in Women With Recurrent Cervical Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Topotecan
- Indications Cervical cancer
- Focus Therapeutic Use
- 15 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Apr 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Aug 2019.
- 19 Apr 2016 Planned initiation date changed from 1 Feb 2016 to 1 Aug 2016.